Bristol-Myers Squibb Company (FRA:BRM)
40.67
-0.06 (-0.16%)
Last updated: Jul 30, 2025
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,191,201
Profits / Employee
$126,077
Market Cap
77.97B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34,100 | 0 | - |
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Siemens Energy AG | 98,000 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Bristol-Myers Squibb Company News
- 7 days ago - Bristol Myers Squibb taps Cristian Massacesi as CMO - Seeking Alpha
- 7 days ago - Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development - Wallstreet:Online
- 9 days ago - Peering Into Bristol-Myers Squibb's Recent Short Interest - Benzinga
- 10 days ago - A Look Into Bristol-Myers Squibb Inc's Price Over Earnings - Benzinga
- 10 days ago - FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks - Benzinga
- 11 days ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 11 days ago - Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally - Benzinga
- 14 days ago - Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer - Seeking Alpha